@article{3052979,
    title = "Campath-1H in B-chronic lymphocytic leukemia: report on a patient
treated thrice in a 3 year period",
    author = "Pangalis, GA and Dimopoulou, MN and Angelopoulou, MK and Tsekouras, CH and and Siakantaris, MP",
    journal = "Medical Oncology",
    year = "2000",
    volume = "17",
    number = "1",
    pages = "70-73",
    publisher = "STOCKTON PRESS",
    issn = "1357-0560, 1559-131X",
    doi = "10.1007/BF02826220",
    keywords = "Campath-1H; monoclonal antibodies; B-CLL",
    abstract = "Monoclonal antibody (mAb) therapy is a novel alternative treatment for
lymphoid malignancies. in this report we present a 55-year-old patient
with B-chronic lymphocytic leukemia, who was initially treated with
chlorambucil p.o. and subsequently with cyclophosphamide iv with poor
response. Then Campath-1H mAb was administered, He received three cycles
of Campath-1H, over a 3yr period, lasting 12 weeks each, at a final dose
of 30mg weekly, on an outpatient basis. After each cycle of Campath-1H
administration there was a significant decrease of the size of the
palpable lymph nodes, spleen and liver. Restoration of the blood
lymphocyte count to normal and a significant decrease of the bone marrow
lymphocytic infiltration was observed at the end of each cycle.
Therefore, a major clinical response was obtained after all cycles.
Campath-1H administration was well tolerated without causing any serious
toxicity."
}